0000899243-20-001131.txt : 20200113 0000899243-20-001131.hdr.sgml : 20200113 20200113180925 ACCESSION NUMBER: 0000899243-20-001131 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200109 FILED AS OF DATE: 20200113 DATE AS OF CHANGE: 20200113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Uihlein Richard E CENTRAL INDEX KEY: 0001694903 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 20524625 MAIL ADDRESS: STREET 1: 12575 ULINE DRIVE CITY: PLEASANT PRAIRIE STATE: WI ZIP: 53158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-09 0 0001133416 GALECTIN THERAPEUTICS INC GALT 0001694903 Uihlein Richard E 12575 ULINE DRIVE PLEASANT PRAIRIE WI 53158 1 0 1 0 Common Stock 2020-01-09 4 A 0 12238 2.86 A 7817678 D Common Stock 27710 I By Ed Uihlein Family Foundation Stock option (right to buy) 2.86 2020-01-09 4 A 0 45000 0.00 A 2030-01-09 Common Stock 45000 45000 D These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2020. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2020. The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934. The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. The options vest 100% on December 31, 2020. /s/ Jack W. Callicutt, by power of attorney 2020-01-13